Biocon Malaysia gets MHRA approval for insulin fill finish unit

Biocon Limited announced that its Malaysian subsidiary has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its new drug product fill finish unit for Semglee® (insulin glargine). This follows a similar approval from the European Medicines Agency (EMA) in July. The facility is located at Biocon's insulin manufacturing site in Malaysia. This development is significant for Biocon's biosimilar insulin production and market expansion in regulated markets.